NCT03038022View on ClinicalTrials.gov

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

December 18, 2017

Study Completion Date

January 15, 2018

Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
DRUG

MGL-3196

Oral

DRUG

Placebo

Oral

Trial Locations (2)

Unknown

Madrigal Research Site, Aalborg

Madrigal Research Site, Viborg

Sponsors
All Listed Sponsors
lead

Madrigal Pharmaceuticals, Inc.

INDUSTRY